CL2025002697A1 - Composición oral sólida de olaparib y sus sales. - Google Patents

Composición oral sólida de olaparib y sus sales.

Info

Publication number
CL2025002697A1
CL2025002697A1 CL2025002697A CL2025002697A CL2025002697A1 CL 2025002697 A1 CL2025002697 A1 CL 2025002697A1 CL 2025002697 A CL2025002697 A CL 2025002697A CL 2025002697 A CL2025002697 A CL 2025002697A CL 2025002697 A1 CL2025002697 A1 CL 2025002697A1
Authority
CL
Chile
Prior art keywords
solid oral
olaparib
salts
oral composition
pharmaceutically acceptable
Prior art date
Application number
CL2025002697A
Other languages
English (en)
Inventor
Mahendrabhai Shah Dharmesh
Aravind Manappa Badiger
Upadhye Abhijeet
Panchal Samir
GOHEL Nishit
G Thakkar Rutvi
Wabale Somnath
Original Assignee
Bdr Pharmaceuticals International Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bdr Pharmaceuticals International Private Ltd filed Critical Bdr Pharmaceuticals International Private Ltd
Publication of CL2025002697A1 publication Critical patent/CL2025002697A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention discloses a novel solid oral pharmaceutical composition of olaparib or pharmaceutically acceptable salts thereof in the solid oral dosage form preferably in the form of a tablet and its process for preparations thereof. The present invention further discloses a solid oral pharmaceutical composition of olaparib or its pharmaceutically acceptable salts thereof along with a hydrophilic matrix polymer.
CL2025002697A 2023-03-09 2025-09-04 Composición oral sólida de olaparib y sus sales. CL2025002697A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202321015565 2023-03-09

Publications (1)

Publication Number Publication Date
CL2025002697A1 true CL2025002697A1 (es) 2026-01-16

Family

ID=92674368

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025002697A CL2025002697A1 (es) 2023-03-09 2025-09-04 Composición oral sólida de olaparib y sus sales.

Country Status (8)

Country Link
EP (1) EP4676484A1 (es)
AU (1) AU2024232985A1 (es)
CL (1) CL2025002697A1 (es)
CO (1) CO2025013863A2 (es)
IL (1) IL323200A (es)
MX (1) MX2025010524A (es)
PE (1) PE20252769A1 (es)
WO (1) WO2024184927A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012205669B2 (en) * 2011-01-10 2015-08-20 Infinity Pharmaceuticals Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN104434809B (zh) * 2014-12-10 2018-10-16 北京科莱博医药开发有限责任公司 一种奥拉帕尼固体分散体制剂及其制备方法
CN108201536A (zh) * 2016-12-16 2018-06-26 中国科学院上海药物研究所 一种奥拉帕尼口服缓控释药物组合物及其用途

Also Published As

Publication number Publication date
WO2024184927A1 (en) 2024-09-12
PE20252769A1 (es) 2025-12-22
IL323200A (en) 2025-11-01
MX2025010524A (es) 2025-11-03
EP4676484A1 (en) 2026-01-14
AU2024232985A1 (en) 2025-10-16
CO2025013863A2 (es) 2025-10-20

Similar Documents

Publication Publication Date Title
BR112023018785A2 (pt) Composto cíclico fundido com pirimidina, método de preparação do mesmo e uso do mesmo
MX2023012361A (es) Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo.
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
PE20180411A1 (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
EA202190650A1 (ru) Замедленная доставка ангиопоэтин-подобных полипептидов 3
BRPI0507628A (pt) composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
MX2023008671A (es) Composicion farmaceutica.
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
MX2023003097A (es) Composiciones farmaceuticas que comprenden un oligonucleotido antisentido para administracion oral.
MX2024010596A (es) Composiciones que comprenden 5-metoxi-2-aminoindano (meai) y n-aciletanolaminas y usos de las mismas
MX2025010524A (es) Composicion oral solida de olaparib y sus sales
JP2019522030A5 (es)
MA62176B1 (fr) Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène
BR112021016795A8 (pt) Administração de inibidor de enzima de ativação de sumo e inibidores de checkpoint
MA31227B1 (fr) Composition pharmaceutique renfermant du phloroglucinol et du paracetamol.
Katakam et al. Design of lamivudine XR matrix tablets: Influence of HPMC and PEO on in vitro drug release and bioavailability in rabbits
CL2022000095A1 (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
Naccarato et al. A case of a probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy
PH12021550251A1 (en) Pharmaceutical composition for oral administration
WO2020175922A3 (ko) 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물
EA202092800A1 (ru) Фармацевтическая композиция немедленного высвобождения для противовоспалительных лекарственных средств с фамотидином и карбонатом
EA202091320A1 (ru) Местное применение диоксидина при инфекционно-воспалительных поражениях эпителия